Study guide
21.2 Haemolytic and Autoimmune Haemolytic Anaemias
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
21.2 Haemolytic and Autoimmune Haemolytic Anaemias
Key Takeaways Explain This Topic AI
Warm autoimmune haemolytic anaemia is IgG-mediated, associated with lymphoma, lupus and methyldopa, and treated with corticosteroids.
Cold agglutinin disease is IgM-mediated, associated with Mycoplasma pneumoniae and Epstein-Barr virus infection and lymphoproliferative disease, and responds poorly to steroids - keeping the patient warm and rituximab are the mainstays.
Intravascular haemolysis produces haemoglobinuria and haemosiderinuria with a very low haptoglobin, whereas extravascular haemolysis produces splenomegaly and jaundice.
Last updated: September 2026
3. Haemolytic Anaemias: Extravascular vs Intravascular Breakdown
Haemolysis represents premature destruction of circulating erythrocytes (normal lifespan ~120 days). The hallmark biochemical features common to all haemolytic states include:
- Elevated serum unconjugated (indirect) bilirubin (from haem catabolism);
- Elevated serum lactate dehydrogenase (LDH; released from lysed red cell cytoplasm); and
Reticulocytosis with polychromasia on peripheral blood film.
Extravascular vs Intravascular Destruction
Extravascular Haemolysis: Erythrocytes are recognized as abnormal and phagocytosed by macrophages within the reticuloendothelial system, predominantly in the splenic cords and hepatic sinusoids. Clinically characterized by splenomegaly , unconjugated jaundice, and elevated urine urobilinogen. Because hemoglobin is broken down intracellularly, free hemoglobin is NOT released directly into plasma; therefore, serum haptoglobin is normal or only mildly decreased, and there is no haemoglobinuria or haemosiderinuria .
Intravascular Haemolysis: Erythrocytes undergo direct mechanical shear, complement-mediated pore formation, or toxin-induced lysis within the circulating blood vessels. Free tetrameric oxyhaemoglobin is released directly into the circulation, binding irreversibly to circulating haptoglobin . The Hb-haptoglobin complex is rapidly cleared by hepatic CD163 scavenger receptors, resulting in profoundly depleted or undetectable serum haptoglobin . Once haptoglobin is completely saturated, free dimeric haemoglobin filters across the renal glomeruli into tubular fluid: excess haemoglobin causes haemoglobinuria (dark brown/black "coca-cola" urine; dipstick positive for blood in the absence of intact red cells on microscopy). Renal proximal tubular cells reabsorb and degrade hemoglobin, storing the iron as haemosiderin; sloughed tubular cells cause haemosiderinuria (detected via Prussian blue staining of urine sediment 5–7 days following acute intravascular haemolysis).
4. Autoimmune Haemolytic Anaemias (AIHA)
Autoimmune haemolytic anaemia is diagnosed by demonstrating autoantibodies and/or complement components deposited on patient red cells via the Direct Antiglobulin Test (DAT / Coombs test) .
- Warm AIHA vs Cold Agglutinin Disease (CAD) Autoimmune Haemolytic Anaemia (AIHA)
- |
- +-------------------------------+-------------------------------+
- | |
- Warm AIHA (80%) Cold Agglutinin Disease (20%)
- IgG autoantibodies (bind at 37°C) - IgM autoantibodies (bind at 4°C)
- Splenic extravascular destruction - Intravascular complement-mediated lysis
- Peripheral microspherocytes - Acrocyanosis triggered by cold exposure
- DAT: IgG positive (± C3d) - DAT: C3d positive, IgG negative
- Causes: Idiopathic, SLE, CLL, lymphoma - Causes: Mycoplasma, EBV, lymphoma
- First-Line: Oral prednisolone (1 mg/kg) - First-Line: Keep warm, Rituximab
- Refractory: Rituximab, splenectomy - STEROIDS & SPLENECTOMY INEFFECTIVE!
Warm AIHA (80% of cases):
Immunoglobulin & Mechanism: Mediated by IgG autoantibodies that react maximally at body temperature ( 37°C ). The Fc portion of IgG-coated erythrocytes is recognized by splenic macrophage Fc-gamma receptors, which partially phagocytose the red cell membrane, transforming them into rigid microspherocytes that undergo extravascular splenic destruction.
DAT Profile: Strongly positive for IgG (and occasionally C3d).
Aetiology: Idiopathic (50%), systemic lupus erythematosus (SLE), chronic lymphocytic leukaemia (CLL), non-Hodgkin lymphoma, and drugs (methyldopa, high-dose penicillin, fludarabine).
Management: First-line therapy is high-dose oral prednisolone (1 mg/kg/day) , achieving remission in 70–80%. Second-line therapy for corticosteroid-dependent or refractory disease is rituximab (anti-CD20 monoclonal antibody) or laparoscopic splenectomy .
Cold Agglutinin Disease (CAD / Cold AIHA, 15–20% of cases):
Immunoglobulin & Mechanism: Mediated by IgM autoantibodies that bind to the I/i carbohydrate antigens on red cells at cold temperatures ( optimal at 0–4°C in the cool acral microcirculation of the fingers, toes, nose, and ears). IgM pentamers crosslink red cells, producing gross intravascular agglutination and activating the classical complement cascade through C3b deposition. Upon warming to 37°C in the core circulation, IgM rapidly dissociates, leaving C3b fixed to the cell surface, leading to terminal complement-mediated intravascular lysis (MAC C5b-9) and hepatic Kupffer cell clearance.
DAT Profile: Characteristically positive for complement C3d only and strictly negative for IgG .
Clinical Picture: Acrocyanosis (painful mottled cyanosis of extremities precipitated by cold exposure, resolving with rewarming, distinct from Raynaud's phenomenon as it lacks reactive hyperaemic rubor), mild jaundice, and dark urine.
Aetiology: Primary chronic CAD (clonal B-cell lymphoproliferative disorder) or secondary reactive cold agglutinin syndrome following Mycoplasma pneumoniae infection (polyclonal anti-I antibodies), Epstein-Barr Virus (EBV / infectious mononucleosis) (polyclonal anti-i antibodies), or low-grade B-cell lymphoma.
CRITICAL EXAM PEARL: In cold agglutinin disease, corticosteroids and splenectomy are completely INEFFECTIVE (because IgM does not depend on splenic Fc receptors for clearance). Management consists of strict avoidance of cold environments , warm clothing, and systemic therapy with rituximab (with or without bendamustine) or the complement C1s inhibitor sutimlimab .
Non-Immune and Microangiopathic Haemolysis
A negative direct antiglobulin test with unequivocal haemolysis shifts the differential to mechanical, infective, toxic and inherited causes.
- Mechanism Examples Film clue
- Microangiopathic TTP, HUS, DIC, malignant hypertension, HELLP syndrome Schistocytes (red cell fragments)
Mechanical Prosthetic valve haemolysis, paravalvular leak, march haemoglobinuria Schistocytes with a metallic valve in the history
Infective Plasmodium falciparum , Clostridium perfringens sepsis, babesiosis Parasites, spherocytes with gas-forming sepsis
- Toxic / oxidative Dapsone, nitrofurantoin, primaquine, naphthalene Bite cells, blister cells, Heinz bodies
- Hypersplenism Portal hypertension, lymphoma Pancytopenia with splenomegaly
Schistocytes plus thrombocytopenia is a medical emergency until TTP has been excluded, because plasma exchange is time-critical and platelet transfusion is harmful.
Drug-Induced Immune Haemolysis
Three mechanisms are distinguished, and MRCP questions test the drug rather than the mechanism name:
Drug adsorption (hapten) — high-dose penicillins and cephalosporins; the antibody is directed at drug bound to the red cell membrane.
Immune complex ("innocent bystander") — quinine, quinidine, rifampicin; often abrupt intravascular haemolysis.
True autoantibody induction — methyldopa, fludarabine, and checkpoint inhibitors; the direct antiglobulin test remains positive for months after the drug is stopped.
Interpreting the Direct Antiglobulin Test
The pattern of the DAT narrows the diagnosis further. IgG-only positivity indicates warm autoimmune haemolysis; complement (C3d)-only positivity indicates cold agglutinin disease or paroxysmal cold haemoglobinuria; both IgG and C3d occur in mixed-type disease and in lupus. Remember that a positive DAT is not synonymous with haemolysis — it is found in a small percentage of healthy blood donors and in patients on intravenous immunoglobulin — so it must always be interpreted alongside reticulocytes, haptoglobin, bilirubin and LDH.
Transfusion Pitfalls
In warm autoimmune haemolytic anaemia the autoantibody is pan-reactive , so it reacts with all donor units and can mask a clinically important alloantibody. Cross-matching therefore takes longer, and the laboratory must be warned early. Transfusion should never be withheld from a patient with critical anaemia while compatibility testing continues, but the transfusion laboratory needs the diagnosis to select the least incompatible units safely. In cold agglutinin disease, blood must be given through a warmer , and the patient kept warm throughout.